Richard Cote M.D.
Chairman & Professor, PathologyRichard J. Cote, M.D., a nationally recognized expert on the cellular and molecular markers of tumor progression in cancer patients, is chair of the Department of Pathology at the University of Miami Miller School of Medicine and the University of Miami Health System, and chief of pathology for Jackson Memorial Hospital.
Cote was at the Keck School of Medicine of the University of Southern California for 18 years before joining the Miller School in 2009. At USC, he was professor of pathology and urology and director of the Genitourinary Cancer Program at USC/Norris Cancer Center. He also directed the Laboratory of Immuno and Molecular Pathology. In 2005, he started and was the director of the Biomedical Nanoscience Program at USC.
Cote has led three of the largest clinical trials in breast, lung and bladder cancer, which were based on discoveries from his research that identified molecules and pathways important in assessing treatment response. A long standing area of focus has been to detect the earliest evidence of tumor spread into blood, bone marrow and lymph nodes in patients with no other evidence of metastatic disease from breast, lung and prostate cancer.
Cote received his medical degree from the University of Chicago Pritzker School of Medicine in 1980. He did a surgical internship at the University of Michigan, a residency in pathology at Cornell University Medical College, and research fellowships at Memorial Sloan-Kettering Cancer Center and New York University School of Medicine. Cote also did a clinical fellowship at Memorial Sloan-Kettering, serving as chief fellow, before moving to USC.
Cote is the recipient of over $35 million in peer reviewed grant support, and holds numerous patents for cancer related and nanoscale technologies. He is the author of over 300 publications, and is the editor and co-author of the standard textbooks “Immuno Microscopy: A Diagnostic Tool for the Surgical Pathologist” (now in its third edition), and “Modern Surgical Pathology,” the second edition of which will be out later this year. He also serves as a member and advisor to a large number of national and international study groups, cancer programs and societies, including the National Cancer Institute. He is the founder of several technology-based companies, including Impath, Inc. and Clarient. He is listed in “Best Doctors in America” and “America’s Top Doctors” and is a Fellow of the Royal College of Pathology.